Halozyme Therapeutics HALO
$91.35 −$1.69 (-1.82%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $91.35 0.00%
Open$93.64
Prev close$93.04
Day range$90.79 – $93.64
Volume1.50M
Market cap$10.41B
P/E (TTM)22.8
Dividend yield–
HALO Stock News
Headlines matching Halozyme Therapeutics or the HALO ticker, most recent first.
- Analysts' Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)
- H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115
- Form 144 | Halozyme Therapeutics(HALO.US) Director Proposes to Sell 3.64 Million in Common Stocks
- Halozyme Therapeutics(HALO.US) Officer Sells US$6.44 Million in Common Stock
- A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $93 to $115
- Halozyme Therapeutics(HALO.US) Officer Sells US$6.28 Million in Common Stock
- RIMBACO: JOINT ANNOUNCEMENT1. CLOSE OF MANDATORY UNCONDITIONAL CASH OFFER BY CMB INTERNATIONAL CAPITAL LIMITED AND CEB INTERNATIONAL CAPITAL CORPORATION LIMITED FOR AND ON BEHALF OF AUREOLE HALO LIMITED TO ACQUIRE ALL THE ISSUED SHARES OF RIMBACO GROUP GLOBAL LIMIT
- H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95
- Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75
- Goldman Sachs Maintains Halozyme Therapeutics(HALO.US) With Sell Rating, Raises Target Price to $57 Positive
- Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $93
- J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)
- China Resources Land Life (1209.HK): A leading operator of consumer‑focused HALO assets in China.
- TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96
- Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $66.41 Negative
No comments yet — be the first to weigh in on HALO.
Sign in to join the discussion.